ClinicalTrials.gg
Not yet recruitingNCT07276945Updated Dec 29, 2025

Individualized Early Diagnosis and Treatment System of Gestational Diabetes Mellitus (GDM) Based on New Continuous Glucose Monitoring (CGM) Technology

An observational study in Gestational Diabetes, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes, Gestational by Peking Union Medical College Hospital — 4 open to participants now, 4 under way, none of them phase 3. Diabetes, Gestational · Peking Union Medical College Hospital.

Started
2025
with 1 other
Observational
9 of 15
2 open now
Registered
15th of 15
by date

Among the 15 studies in Diabetes, Gestational by Peking Union Medical College Hospital, this one is one of 2 that started in 2025, is one of 9 observational ones, and was the 15th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

4 of the 15 studies in Diabetes, Gestational by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes, Gestational by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

Gestational diabetes mellitus (GDM), as the most common metabolic complication of pregnancy, poses a serious threat to maternal and fetal metabolic health. However, current GDM diagnosis faces several problems such as static, single-point, cumbersome to operate and delayed diagnosis, highlighting an urgent need to establish an individualized system for early prediction, diagnosis, and intervention.

This project aims to develop a mother-child cohort covering pregnancy and the perinatal period to propose early diagnostic criteria for GDM based on continuous glucose monitoring (CGM) technology, as well as developing clinically applicable AI-based tools for analyzing and interpreting CGM data, along with strategies to assist in GDM diagnosis. Furthermore, it will investigate CGM parameters and multi-omics biomarkers suitable for predicting maternal and fetal outcomes, culminating in the creation of an intelligent management platform for GDM. This project is expected to enhance the early identification rate of gestational diabetes, potentially advancing the diagnostic and therapeutic window for the condition, thereby improving both short- and long-term maternal and fetal health outcomes.

Read the detailed description

China has a diabetic population of 233 million, posing an enormous societal burden. Early recognition and intervention for diabetes are urgently needed. In recent years, growing evidence has highlighted the critical role of the early-life developmental environment in the pathogenesis of diabetes. As early as 1986, Professor Barker proposed the Developmental Origins of Health and Disease (DOHaD) theory. The investigators previously validated this theory for the first time in the Chinese population through cohort studies, demonstrating that adverse intrauterine environments lead to abnormal glucose metabolism in offspring and that early-life interventions can effectively prevent adult-onset diabetes.

According to the International Diabetes Federation's Diabetes Atlas (11th edition), the global incidence of hyperglycemia during pregnancy is 16.7%, with gestational diabetes mellitus (GDM) accounting for up to 80% of cases. This means that one in five live births is exposed to an adverse intrauterine environment early in life, increasing their risk of metabolic disorders such as overweight, obesity, and diabetes in adulthood. GDM significantly raises the risk of adverse pregnancy outcomes and seriously threatens the metabolic health of both mothers and offspring. Early and efficient diagnosis and prevention of GDM are therefore crucial for improving metabolic health in mothers and children.

The current diagnosis of GDM relies on oral glucose tolerance tests (OGTT) performed at 24-28 weeks of gestation, which present limitations such as static and single-time-point measurement, operational complexity, delayed diagnosis, and limited time for effective intervention. Thus, there is an urgent need to develop novel technologies for early prediction and diagnosis of GDM.

Continuous glucose monitoring (CGM) in the first trimester offers advantages including 24/7 detailed glucose data, detection of hidden hyperglycemia, assessment of glycemic variability, and compatibility with AI-assisted analysis, showing great potential for early diagnosis and management of GDM. Previously, the investigators applied CGM in patients with type 2 diabetes and was granted a Chinese invention patent for "Using CGM for Improved Management and Monitoring of Glucose in Type 2 Diabetes (CN 109637677A)." In recent years, CGM has been widely used in diabetes management and has begun to be applied in managing HbA1c levels in pregnant women with type 1 diabetes. However, research on its use in pregnant women with type 2 diabetes and GDM is still in its early stages. There is currently a lack of studies utilizing CGM combined with artificial intelligence for early diagnosis and prediction of GDM in the first trimester.

Besides, multiple studies have explored risk factors and biomarkers for GDM to enable early screening and predict maternal and fetal outcomes. However, most research has been limited to single-omics approaches or later gestational time points, presenting numerous constraints. Studies conducted at earlier gestational periods, across multiple time points, and utilizing multi-omics approaches will further reveal biomarkers predictive of maternal and fetal outcomes in GDM.

Therefore, the investigators plan to establish a GDM mother-child cohort covering the pregnancy and perinatal periods. They aim to propose early diagnostic criteria for GDM based on CGM, develop clinically applicable AI-driven tools for analyzing and interpreting CGM data, and formulate auxiliary diagnostic strategies for GDM. The investigators will explore CGM parameters and multi-omics biomarkers suitable for predicting maternal and fetal outcomes. Based on these findings, the investigators are expected to establish an intelligent management platform for GDM, which will move forward the clinical window for GDM diagnosis and treatment, improving both short- and long-term health outcomes for mothers and their offspring.

03

Conditions studied

  • Gestational Diabetes

Keywords

  • gestational diabetes mellitus
  • continuous glucose monitoring
  • early diagnosis
  • mother-child outcomes
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

women with gestational diabetes and control group

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ① Early pregnancy (≤14 weeks) pregnant women;
  • ② Singleton pregnancies;
  • ③ Early pregnancy psychological scores (PHQ-9 and GAD-7) \<10 points;
  • ④ Consent to participate in the study and sign an form.

Exclusion criteria

Exclusion Criteria:

  • ① Twin or multiple pregnancies;
  • ② Diabetes mellitus complicated with pregnancy;
  • ③ Severe pregnancy complications;
  • ④ Pre-existing significant cardiovascular, hepatic, renal, hematologic, or diseases;
  • ⑤ History of smoking, alcohol abuse, or narcotic and drug use;
  • ⑥ Early pregnancy psychological assessment (PHQ-9 or GAD-7) score ≥10.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • gestational diabetes group

    No interventions

    Other: No interventions

  • healthy control group

    No interventions

    Other: No interventions

Interventions

  • OtherNo interventions

    No interventions

06

What researchers measure

Primary outcomes

  1. Oral Glucose Tolerance Test

    Time frame: 24~28 weeks of pregnancy

Secondary outcomes

  1. Adverse maternal and fetal outcomes (Large for Gestational Age and Small for Gestational Age)

    Time frame: up to 42 weeks of pregnancy

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jul 2028, 30 months later.

Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 30 months is below that.

Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2025
First posted
Dec 11, 2025
StartEst.
Dec 10, 2025
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2028
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07276945
Responsible party
Xinhua Xiao (Chief physician, Peking Union Medical College Hospital) — Principal investigator
First posted
Dec 11, 2025
Start date
Dec 10, 2025 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Dec 29, 2025

Study contacts

Xinhua Xiao
Contact
xiaoxh2014@vip.163.com
86-10-13911830085
Xinhua Xiao
study director · Key Laboratory of Endocrinology, Ministry of Health, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion